Metvix

Methyl aminolevulinate, the active ingredient in Metvix, is a photosensitizer presented as a 16% w/w cream for topical use. It treats actinic keratosis and superficial basal cell carcinoma in adult patients with skin lesions.

GNH USA supplies Metvix as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metvix is employed in dermatologic photodynamic therapy for premalignant and early malignant skin lesions.

- Actinic keratosis: clears dysplastic lesions and reduces the risk of progression to invasive carcinoma. - Superficial basal cell carcinoma: provides selective cytotoxicity of tumor cells, leading to lesion resolution.

Metvix may cause a range of local and systemic reactions after application and light activation.

Common Side Effects: - Erythema: redness at the treatment site. - Edema: swelling of the treated area. - Pain or burning sensation during illumination. - Itching or mild pruritus.

Serious or Rare Side Effects: - Severe photosensitivity reactions extending beyond the treated field. - Allergic dermatitis or hypersensitivity rash. - Secondary bacterial infection of the treated skin. - Persistent scarring or hyperpigmentation of the lesion site.

When using Metvix, several safety measures should be observed.

- Patient selection: limit use to adults with confirmed actinic keratosis or superficial basal cell carcinoma. - Light exposure: avoid direct sunlight on treated skin for the recommended post‑treatment period. - Skin assessment: perform thorough examination of the lesion before and after therapy. - Pregnancy and lactation: safety not established; avoid use in pregnant or breastfeeding individuals. - Store at room temperature: keep cream in the original container, protect from light and moisture.

Metvix may interact with other agents that affect photosensitivity or wound healing.

Major Interactions (Avoid): - Concurrent photosensitizing drugs: may increase risk of severe photosensitivity. - Systemic porphyrinogenic agents: could amplify reactive oxygen species formation. - Topical retinoids: may exacerbate local skin irritation.

Moderate Interactions (Monitor Closely): - Anticoagulants: monitor for bleeding if extensive skin injury occurs. - Immunosuppressants: may impair healing of treated lesions.